Telix Pharmaceuticals Limited (TLX) Fair Value & Analysis
Healthcare · US · Market cap $3.6B
Telix Pharmaceuticals Limited
TLX · US
Fair value as of: Jun 24, 2026
From 9 valuation models · updated 5 days ago
Share price +19.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $5.79 – $15.29 · fair‑value band $1.55 – $3.37 · the $10.21 price screens above the $3.37 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Telix Pharmaceuticals Limited (TLX) currently trades at $10.21, while our model-based Fair Value estimate is $3.37 — implying the stock looks roughly 67.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Telix Pharmaceuticals Limited generated revenue of $804M at a net margin of -0.9%. Revenue grew 49.3% year over year. It earns a return on equity of -1.9%. Net debt stands at $487M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients w…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Telix Pharmaceuticals Limited reported revenue of $1.2B in FY2025 versus $7.6M in FY2021, a compound +254.9%/yr. Reported net income was −$10.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Telix Pharmaceuticals Limited (TLX) undervalued?
What is the fair value of TLX?
What is the quality score of TLX?
What is the revenue of Telix Pharmaceuticals Limited (TLX)?
What is the net profit margin of TLX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.